Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist
Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.
Featured in the New York Times, Griffiths is a psychopharmacologist and professor of neuroscience, psychiatry and behavioral studies. He is the founding director of the Center for Psychedelic and Consciousness Research at the same institution where he is now passing the torch for others to keep advancing the science of psychedelics. Read more HERE.
LSD Microdosing To Ease Cancer-Related Distress: Phase 2 Clinical Trial Gets Green Light
Australia-based MindBio Therapeutics Corp., an ex-subsidiary to Blackhawk Corp. received ethics approval for a Phase 2 clinical trial assessing the effects of LSD microdoses paired with meaning-centered psychotherapy for patients with advanced-stage cancer.
The randomized, double-blind, placebo-controlled study follows positive outcomes from a Phase 1 trial on healthy volunteers including increases in energy, social connectivity, creativity, wellness and happiness as well as tolerance to the LSD microdoses. Read more HERE.
Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment
Clearmind Medicine Inc. (NASDAQ: CMND), an Israeli biotech company received approval from the IMCA center’s Ethics Committee for the announced Phase 1/2 clinical trial assessing its proprietary MEAI-based compound, CMND-100, for the treatment of Alcohol Use Disorder (AUD.) Clearmind discovers and develops novel psychedelic-derived therapeutics for major undertreated health problems.
The Ethics …